News
News
13 January 2020
14 November 2019
New grant for membrane protein stabilization chemistry
CALIXAR, the French biotech company specialized in the native isolation of membrane therapeutic targets/antigens and the French University of Avignon – Bio-organic Chemistry and Amphiphilic Systems Team (CBSA) – announce new grant approval for the CHEM2STAB common laboratory (CHEMistry for STABilization) from the French National Research Agency (ANR).
24 October 2019
New vaccine formulation against influenza infection
Calixar announces the publication of a new article in Vaccine by Calixar in collaboration with the VirPath laboratory (Lyon) and International infectious diseases Research Center, Quebec (Laval University). This publication describes an improved process to formulate the influenza vaccine since it allows the same protection in animals and neutralizing antibody responses but with 10 to 30-fold less antigen than the commercialized trivalent inactivated vaccines Vaxigrip® or Fluviral®.
15 October 2019
Novel influenza vaccine : Calixar patent granted in Europe
After the United States Patent Office in last June, CALIXAR announces the grant of its patent by the European Patent Office concerning the preparation of vaccine antigens using an innovative splitting approach for the formulation of novel vaccines (EP3194433). This patent issued from the fruitful collaboration with the academic laboratory VirPath is a great step forward in the generation of safer and more efficient vaccine candidates.
23 September 2019
New publication on Calixar's stabilization expertise for native MPs
Calixar announces the publication of a new article by Calixar in collaboration with Roche Pharmaceuticals and The University of Basel (Biozentrum) in Scientific Reports.
6 September 2019
Novel innovative detergent family for MP extraction and stabilization
CALIXAR announces the publication of a new article in the framework of the CHEM2STAB common laboratory.
4 September 2019
Calixar novel patent publication
CALIXAR announces the official grant of its patent by the European Patent Office
26 August 2019
New publications on MRP4 solubilization and stabilization
CALIXAR announces the publication of new studies on MRP4 solubilization and stabilization in collaboration with Aston University.
17 June 2019
Calixar and VirPath patent granted in the United States
CALIXAR announces the grant of its patent by the United States Patent and Trademark Office for the preparation of vaccine antigens using an innovative splitting approach for the formulation of novel vaccines (US 10144917 B2).
29 May 2019
New glycosylated calixarene-based detergent for MP stabilization
CALIXAR announces the publication of a new article in collaboration with Gregory Durand’s laboratory.